What Is Regeneron Pharmaceuticals, Inc. (REGN) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Regeneron Pharmaceuticals, Inc.'s intrinsic value is estimated at $526.70. Trading at its current price of $663.09, the valuation engine raises significant caution: 10 of 13 models flag downside risk, projecting an average implied return of -20.6%. The most optimistic model, First Chicago, places fair value at $676.15 (+2.0%), while Dynamic NAV — the most conservative — estimates $177.80 (-73.2%). This +75.2% gap reflects genuine analytical uncertainty about Regeneron Pharmaceuticals, Inc.'s intrinsic worth.
What Do the Models Say About REGN?
13 of 13 models are currently active for REGN. Of these, 2 models suggest upside while 11 models suggest overvaluation. The Bayesian DCF estimates REGN's intrinsic value at $639.93, implying -3.5% downside from the current price. See which stocks rank higher →
How Does REGN Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, REGN ranks #10 by Quality of Company score. CirclFi's QOC score of 9.6/10 evaluates 32 fundamental signals. A score of 9.6 places REGN in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Regeneron Pharmaceuticals, Inc., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.
Is REGN a Value Trap?
CirclFi's Value Trap algorithm assigns REGN a score of 8/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Regeneron Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Regeneron Pharmaceuticals, Inc. scores 9.6 out of 10 on our 32-signal quality assessment, a elite rating that ranks among the highest-quality businesses in our coverage universe. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +75.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every REGN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across REGN's 13 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad